User login
In his first podcast for 2013, Dr. David Henry, Editor in Chief of Community Oncology, highlights an article on the impact of pretreatment positron emission tomography on disease control and treatment decisions in advanced esophageal cancer and another on the relationship between patient age, comorbidities, and neutropenic complications in patients receiving myelosuppressive chemotherapy. Other highlights include a Community Translations essay and accompanying Commentary on the recently approved regorafenib for previously treated metastatic colorectal cancer.
In his first podcast for 2013, Dr. David Henry, Editor in Chief of Community Oncology, highlights an article on the impact of pretreatment positron emission tomography on disease control and treatment decisions in advanced esophageal cancer and another on the relationship between patient age, comorbidities, and neutropenic complications in patients receiving myelosuppressive chemotherapy. Other highlights include a Community Translations essay and accompanying Commentary on the recently approved regorafenib for previously treated metastatic colorectal cancer.
In his first podcast for 2013, Dr. David Henry, Editor in Chief of Community Oncology, highlights an article on the impact of pretreatment positron emission tomography on disease control and treatment decisions in advanced esophageal cancer and another on the relationship between patient age, comorbidities, and neutropenic complications in patients receiving myelosuppressive chemotherapy. Other highlights include a Community Translations essay and accompanying Commentary on the recently approved regorafenib for previously treated metastatic colorectal cancer.